Collectively, we assume that inhibition of the EGFR-HIF1a signaling pathway by EGFR-TKI administration suppressed the expression of HIF1a in the tumor, resulting in lower angiogenetic activity and leading to the lack of PTBE on imaging. The gene discussed is EGFR; the disease is neoplasm.